Data from >50K commercial and Medicare claims in RA patients shows the risk of VTE (DVT/PE) to No different comparing pts on tofacitinib vs TNFi (HR 1.33; 95% CI, 0.78-2.24). Abst L09 #ACR18 https://t.co/dafoEcl9pD